FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder. Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years.
Are you looking for or in search of FDA approved “dupilumab injection in India”? “Medicant Healthcare” a registered pharmacy firm in India deals in both brand name as well as generic name Drugs / medicine approved for allergic diseases such as eczema (atopic dermatitis), asthma and nasal polyps which result in chronic sinusitis. Need Access of dupilumab injection, get in touch with our healthcare professional.
DUPIXENT is an interleukin-4 receptor alpha antagonist indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.
Dupilumab, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as eczema (atopic dermatitis), asthma and nasal polyps which result in chronic sinusitis. It is also used for the treatment of eosinophilic esophagitis.